UBS Group
CAI

UBS Group’s Caris Life Sciences CAI Stock Holding History

UBS Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.1M Buy
2,745,811
+561,831
+26% +$12.3M 0.01% 1665
2025
Q4 		$58.9M Buy
2,183,980
+1,948,107
+826% +$54.9M 0.01% 1458
2025
Q3 		$7.14M Buy
+235,873
New +$7.52M ﹤0.01% 3662

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group's CAI Position: Q1 2026 in Review

UBS Group increased its Caris Life Sciences (CAI) stake by 26% in Q1 2026, buying an estimated $12.3M and bringing the position to 2,745,811 shares worth $49.1M. The position accounts for 0.01% of the portfolio, ranked #1665.

UBS Group first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. The position peaked at $58.9M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • UBS Group held 2,745,811 shares of Caris Life Sciences worth $49.1M as of Q1 2026.
  • UBS Group bought 561,831 Caris Life Sciences shares in Q1 2026, an estimated $12.3M.
  • Caris Life Sciences made up 0.01% of UBS Group's portfolio in Q1 2026, its #1665 holding.
  • UBS Group first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • UBS Group's Caris Life Sciences position peaked at $58.9M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.